KORU Medical Systems Announces Third Quarter 2026 Results Including Second Consecutive Quarter of Positive Net Income and Adjusted EBITDA
Key Highlights
- ➤Q3 revenue $11.6 million, up 11% year over year
- ➤Net income $0.2 million versus prior-year $0.8 million loss
- ➤Adjusted EBITDA $1.3 million, up from $0.1 million
- ➤2026 revenue guidance raised to $48.0-$48.5 million
- ➤Full-year gross margin guidance raised to 63%-64%
Expert Statements
Adam Kalbermatten, President and CEO of KORU Medical
“Total Revenue of $11.6 million represents another quarter of consistent above-market growth for KORU, driven by our recurring patient base.”
Adam Kalbermatten, President and CEO of KORU Medical
“We also delivered positive net income and adjusted EBITDA for the second consecutive quarter, demonstrating the scalability of our business model.”
Adam Kalbermatten, President and CEO of KORU Medical
“As anticipated, our year-over-year revenue growth moderated in the third quarter compared to the first half of 2026, reflecting in part the timing of our entry into a competitive non-tender market in Europe.”
Adam Kalbermatten, President and CEO of KORU Medical
“With that market launch now behind us, we anticipate revenue growth to reaccelerate in the fourth quarter for a strong finish to the year.”
Adam Kalbermatten, President and CEO of KORU Medical
“We are encouraged by our geographic expansion, specialty pharmacy partnerships, and pipeline advancements and plan to continue investing resources in our long-term growth strategy as we move forward.”
KORU Medical Systems Announces Third Quarter 2026 Results Including Second Consecutive Quarter of Positive Net Income and Adjusted EBITDA
KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the third quarter ended September 30, 2026.
Get started
Create a free account to read the full story.